Avantor (NYSE:AVTR) Price Target Cut to $29.00 by Analysts at UBS Group

Avantor (NYSE:AVTR) had its price target trimmed by UBS Group from $30.00 to $29.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. Morgan Stanley upped their price target on shares of Avantor from $28.00 to $29.00 and gave the company an overweight rating in a research note on Monday, July 29th. Robert W. Baird increased their price objective on shares of Avantor from $26.00 to $27.00 and gave the company an outperform rating in a research report on Monday, July 29th. Wells Fargo & Company started coverage on shares of Avantor in a report on Tuesday, August 27th. They set an overweight rating and a $30.00 target price for the company. Royal Bank of Canada reaffirmed an outperform rating and set a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Finally, Barclays boosted their price target on shares of Avantor from $25.00 to $28.00 and gave the company an overweight rating in a research report on Monday, July 29th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $28.00.

Avantor Stock Performance

Shares of AVTR stock opened at $24.47 on Tuesday. Avantor has a one year low of $16.63 and a one year high of $28.00. The firm has a 50-day moving average of $25.71 and a 200-day moving average of $24.36. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. The company has a market cap of $16.62 billion, a P/E ratio of 62.74, a P/E/G ratio of 2.71 and a beta of 1.33.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Friday, July 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. The business had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.70 billion. Avantor had a net margin of 5.28% and a return on equity of 12.40%. Equities research analysts forecast that Avantor will post 1.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at approximately $740,372.64. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Avantor

Several large investors have recently modified their holdings of the stock. Versant Capital Management Inc lifted its holdings in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after acquiring an additional 1,102 shares during the last quarter. Blue Trust Inc. increased its position in shares of Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after buying an additional 1,391 shares during the period. UMB Bank n.a. purchased a new stake in Avantor in the third quarter worth about $49,000. GAMMA Investing LLC grew its holdings in Avantor by 89.9% in the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new position in shares of Avantor in the first quarter worth approximately $93,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.